Increased Serum ANGPTL8 Concentrations in Patients with Prediabetes and Type 2 Diabetes
Table 1
Characteristics of 129 subjects, including a statistical comparison of characteristics of subjects with NGR, IFG, IGT, CGI, and T2DM.
NGT (22)
IFG (30)
IGT (32)
CGI (12)
T2DM (33)
Value
Gender (M/F)
6/16
17/13
14/18
6/6
21/12
8.026
0.091
Age (years)
54.41 ± 5.59
57.66 ± 5.50
58.09 ± 6.47
58.17 ± 8.33
60.18 ± 5.86
2.923
0.024
d
BMI (kg/m2)
24.21 ± 3.17
25.44 ± 2.63
25.14 ± 3.18
27.20 ± 3.25
26.53 ± 3.36
2.802
0.029
c
Waist circumferences (cm)
79.89 ± 7.29
85.54 ± 7.10
84.25 ± 7.59
89.12 ± 9.16
87.58 ± 7.61
4.432
0.002
a, c, d
WHR
0.85 ± 0.05
0.90 ± 0.04
0.88 ± 0.04
0.91 ± 0.05
0.90 ± 0.04
3.927
0.005
a, b, c, d
SBP (mmHg)
127.00 ± 13.82
128.07 ± 13.55
130.06 ± 14.63
131.67 ± 13.06
132.79 ± 10.62
0.860
0.490
DBP (mmHg)
80.82 ± 7.24
80.69 ± 5.91
82.12 ± 7.14
83.67 ± 6.25
84.18 ± 7.63
1.359
0.252
TC (mmol/L)
1.09 (0.77–2.11)
1.95 ± 1.16
2.13 (1.38–3.05)
1.86 (1.20–3.33)
2.02 ± 0.99
7.540
0.110
TG (mmol/L)
0.44 ± 0.17
0.65 (0.37–1.10)
0.67 (0.47–1.37)
0.65 (0.43–1.01)
0.67 (0.44–1.13)
12.782
0.012
a, b, d
LDL-C (mmol/L)
0.84 ± 0.59
0.92 ± 0.75
1.06 ± 0.69
1.20 ± 0.90
0.98 ± 0.58
0.714
0.584
HDL-C (mmol/L)
0.53 ± 0.27
0.57 ± 0.38
0.68 ± 0.36
0.71 ± 0.53
0.65 ± 0.36
0.902
0.465
HbA1C (mmol/L)
5.52 ± 0.31
5.58 ± 0.28
5.67 ± 0.34
5.71 ± 0.33
6.96 ± 1.66
14.084
<0.001
d, g, i, j
FPG (mmol/L)
4.92 ± 0.35
5.96 ± 0.27
5.17 (5.02–5.42)
6.09 (5.75–6.41)
7.40 (6.71–8.55)
97.295
<0.001
a, c, d, e, g, h, i, j
PPG (mmol/L)
6.72 (5.89–6.95)
6.23 ± 1.09
8.50 (8.12–9.80)
9.25 (8.21–9.79)
14.51 ± 4.26
105.764
<0.001
b, c, d, e, f, g, i, j
FINS (mIU/L)
1.80 (1.37–3.62)
3.45 (1.98–4.99)
3.39 (2.46–6.44)
5.67 (2.98–7.59)
4.36 (2.12–8.65)
18.375
0.001
c, d
Fasting C-peptide (ng/mL)
1.18 ± 0.80
1.50 ± 0.60
1.49 ± 0.84
1.64 ± 0.87
1.86 ± 1.18
2.864
0.026
c, d
PINS (mIU/L)
10.72 (6.13–15.20)
17.54 (6.98–34.68)
35.26 (23.84–51.49)
38.60 (23.52–58.64)
21.22 (11.59–39.48)
31.364
<0.001
b, c, d
Postprandial C-peptide (ng/mL)
4.60 ± 3.55
5.76 ± 3.55
7.73 ± 4.16
8.84 ± 6.04
6.53 ± 3.70
4.191
0.003
c
HOMA-IR
0.39 (0.28–0.81)
0.92 (0.55–1.31)
0.78 (0.55–1.48)
1.37 (0.80–1.92)
1.31 (0.71–2.76)
30.318
<0.001
a, c, d
HOMA-BETA
28.51 (18.22–43.93)
28.42 (15.58–39.25)
40.71 (30.44–71.99)
40.21 (19.75–61.17)
20.46 (10.84–46.72)
9.942
0.041
i
BETA/IR
52.10 ± 24.68
25.85 ± 2.87
52.14 (43.16–58.78)
28.52 (23.64–34.99)
15.59 (10.43–20.84)
30.318
<0.001
a, c, d, e, g, h, i
ΔI120/ΔG120
4.58 (1.47–7.59)
7.78 (−4.11–29.83)
9.56 (5.34–12.76)
10.53 (5.81–18.71)
2.35 (1.02–5.08)
20.733
<0.001
i, j
ΔI120/ΔG120/IR
9.51 (3.21–17.00)
11.15 (−3.47–20.54)
10.58 (6.08–16.19)
8.04 (3.64–15.94)
1.86 (0.81–3.36)
26.967
<0.001
d, g, i, j
ANGPTL8 (ng/mL)
0.38 ± 0.25
1.07 ± 0.52
0.92 ± 0.57
1.23 ± 0.48
0.85 ± 0.67
25.974
<0.001
a, b, c, d
M: male; F: female; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FINS: fasting serum insulin; PINS: postprandial serum insulin; HOMA-IR: homoeostasis model assessment of insulin resistance; HOMA-BETA: homoeostasis model assessment of beta cell function index. Pairwise comparisons: a, NGT versus IFG; b, NGT versus IGT; c, NGT versus CGI; d, NGT versus T2DM; e, IFG versus IGT; f, IFG versus CGI; g, IFG versus T2DM; h, IGT versus CGI; i, IGT versus T2DM; and j, CGI versus T2DM.
